Allopurinol News and Research RSS Feed - Allopurinol News and Research

Study throws light on why gout not well managed in many patients

Study throws light on why gout not well managed in many patients

A study published online this month in the Arthritis Care and Research journal is shedding light on why gout, a painful and common form of arthritis, is not well managed in many patients. The journal is published by the American College of Rheumatology. [More]
Presence of tophi in people with gout can increase risk of developing cardiovascular disease

Presence of tophi in people with gout can increase risk of developing cardiovascular disease

The presence of tophi - crystal deposits of uric acid found on the surface of the joints or in the skin and cartilage - in people with gout can increase their risk of developing cardiovascular disease, according to research presented this week at the American College of Rheumatology Annual Meeting in San Francisco. [More]
UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern evaluates allopurinol drug to prevent nephropathy in Type I diabetes patients

UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes. [More]
University of Otago research backs the belief that eating tomatoes can cause gout to flare up

University of Otago research backs the belief that eating tomatoes can cause gout to flare up

People who maintain that eating tomatoes can cause their gout to flare up are likely to welcome new research from New Zealand's University of Otago that has, for the first time, found a biological basis for this belief. [More]
CU researcher awarded NIH grant to study benefit of allopurino drug in lowering uric acid levels

CU researcher awarded NIH grant to study benefit of allopurino drug in lowering uric acid levels

Kidney disease poses one of the greatest burdens for people living with type 1 diabetes. A study newly awarded by the National Institutes of Health will look at whether lowering uric acid levels can prevent people with type 1 diabetes from needing hemodialysis or kidney transplant. [More]
Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Urate-lowering therapy alone may not directly reduce the risk of kidney disease in those with hyperuricemia. However, according to a study presented at the American College of Rheumatology Annual Meeting in San Diego, working to lower serum uric acid based on the 2012 American College of Rheumatology Guidelines for Management of Gout has a positive effect. [More]
Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes. [More]
Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years. [More]
Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout is a relatively common arthritic disease that affects about 4% (I in 25) of the population. It results from the deposition of uric acid in joints due to elevated blood levels and a resulting inflammation ensues which is very painful. [More]
Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

The painful rheumatic condition gout is often associated with the big toe, but it turns out that patients at highest risk of further flare-ups are those whose gout first involved other joints, such as a knee or elbow, Mayo Clinic has found. [More]
Vitamin C and gout: an interview with Prof. Lisa Stamp

Vitamin C and gout: an interview with Prof. Lisa Stamp

A previous study in by Choi et al in the USA showed that people with a higher vitamin C intake have a lower risk of gout. There are also studies in healthy volunteers that suggest that vitamin C supplements reduce blood uric acid levels. [More]
Research reveals vitamin C does not reduce urate levels in gout patients

Research reveals vitamin C does not reduce urate levels in gout patients

Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism. [More]
Allopurinol may improve CV outcomes in kidney disease

Allopurinol may improve CV outcomes in kidney disease

The xanthine oxidase inhibitor allopurinol appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality in patients with hypertensive nephropathy, show findings from a Japanese study. [More]
Two-part ACR guidelines on gout

Two-part ACR guidelines on gout

Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR). [More]
Cherry intake reduces risk of gout attacks

Cherry intake reduces risk of gout attacks

A new study found that patients with gout who consumed cherries over a two-day period showed a 35% lower risk of gout attacks compared to those who did not eat the fruit. [More]
Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment. [More]
Steroids may slow progression of life-threatening skin reactions

Steroids may slow progression of life-threatening skin reactions

Multi-national study results show that the progression of Steven Johnson Syndrome or Toxic Epidermal Necrolysis may be lengthened if corticosteroids are used prior to the onset of either condition. [More]
Risk of gout flare-ups greatly increased by purine rich foods

Risk of gout flare-ups greatly increased by purine rich foods

Foods rich in purines, particularly those found in meat and seafood, quintuple the immediate risk of a gout flare-up, finds research published online in the Annals of the Rheumatic Diseases. [More]
Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout. [More]
BioCryst first quarter revenues increase to $12.2 million

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012. [More]
Advertisement
Advertisement